EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Primary aldosteronism 2.0: an update for clinicians on diagnosis and treatment

Stefan Pilz, Tomaz Kocjan, Verena Theiler-Schwetz, Christian Trummer

Polish Archives of Internal Medicine · 2023

DOI: 10.20452/pamw.16585 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Polish Archives of Internal Medicine, 2023. Verfasst von Stefan Pilz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria. stefan.pilz@medunigraz.at. Hauptthemen laut MEDLINE: Hyperaldosteronism. Die Arbeit wurde bisher 4-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary aldosteronism (PA), characterized by inappropriately high concentrations of the adrenal-derived hormone aldosterone, is the most common endocrine cause of arterial hypertension. As compared with individuals with essential hypertension, patients with PA have a significantly increased cardiovascular risk that cannot be fully reversed by common antihypertensive treatment because of blood pressure-independent deleterious effects of aldosterone. Measurement of the aldosterone to renin ratio (ARR), reflecting the degree of aldosterone excess, is the classic screening test for PA, but thresholds for an elevated ARR vary substantially and are arbitrary, as there exists a wide disease continuum that spans from preclinical stages to overt PA. Treatment approaches for PA with either mineralocorticoid receptor antagonists for bilateral disease or unilateral adrenalectomy for aldosterone-producing adenomas (APA) are highly effective to mitigate the excess cardiovascular risk associated with PA. Subtype classification according to the dichotomous concept of unilateral PA, mainly due to APAs, vs bilateral PA, mainly due to bilateral adrenal hyperplasia, has been recently challenged by advances in the pathophysiologic understanding and therapeutic spectrum of PA. The implementation of current PA guidelines into clinical routine is extremely poor, as reflected by the fact that most patients suffering from PA remain undiagnosed and probably untreated. Pragmatic approaches are required to address this public health problem. In this review, we present an up‑to‑date overview on the clinical significance, diagnosis, and treatment of PA, with the aim to provide guidance for clinicians regarding the management of this disease, paying particular attention to its feasible implementation into daily clinical routine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperaldosteronismHumansAdrenalectomyAdrenocortical AdenomaAldosteroneHypertension

Substanzen

Aldosterone

Autor:innen und Institutionen

  • Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria. stefan.pilz@medunigraz.at
  • Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia
  • Department of Internal Medicine, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
  • Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria

Zitieren

APA

Pilz, S., Kocjan, T., Theiler-Schwetz, V., & Trummer, C. (2023). Primary aldosteronism 2.0: an update for clinicians on diagnosis and treatment. Polish Archives of Internal Medicine. https://doi.org/10.20452/pamw.16585

Vancouver

Pilz S, Kocjan T, Theiler-Schwetz V, Trummer C. Primary aldosteronism 2.0: an update for clinicians on diagnosis and treatment. Polish Archives of Internal Medicine. 2023. doi:10.20452/pamw.16585

BibTeX
@article{Pilz2023,
  author = {Pilz, Stefan and Kocjan, Tomaz and Theiler-Schwetz, Verena and Trummer, Christian},
  title = {Primary aldosteronism 2.0: an update for clinicians on diagnosis and treatment},
  journal = {Polish Archives of Internal Medicine},
  year = {2023},
  doi = {10.20452/pamw.16585}
}
Kostenlos starten →